Dialysis-related carnitine disorder

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

L-carnitine plays an essential role in the β-oxidation of fatty acids by catalyzing their transport into the mitochondrial matrix. The kidney maintains plasma free L-carnitine levels in the homeostatic range by selective saturable tubular reabsorption. The preferential retention of free L-carnitine over acyl-L-carnitines by the kidney is lost in patients with end-stage renal disease (ESRD). Loss of renal parenchyma as a site of carnitine synthesis, as well as nonselective clearance of L-carnitine by the dialysis procedure lead to dialysis-related carnitine deficiency. Numerous studies investigating whether L-carnitine supplementation will alleviate several dialysis-related symptoms, such as intradialytic hypotension, heart failure, muscle weakness, low exercise capacity, and anemia, have reported conflicting results. Many of these studies suffer from a lack of randomization and control groups, heterogeneity in the administration of L-carnitine, and nonstandardized measures of symptom improvement. More data exist to support the use of L-carnitine in selected anemic dialysis patients with very large erythropoietin requirements in whom extensive examination for reversible causes of anemia was unrevealing.

Original languageEnglish (US)
Pages (from-to)323-328
Number of pages6
JournalSeminars in Dialysis
Volume19
Issue number4
DOIs
StatePublished - Jul 1 2006

Fingerprint

Carnitine
Dialysis
Kidney
Anemia
Muscle Weakness
Random Allocation
Erythropoietin
Hypotension
Chronic Kidney Failure
Myocardium
Fatty Acids
Heart Failure
Exercise
Control Groups

ASJC Scopus subject areas

  • Nephrology

Cite this

Dialysis-related carnitine disorder. / Susan Hedayati, S.

In: Seminars in Dialysis, Vol. 19, No. 4, 01.07.2006, p. 323-328.

Research output: Contribution to journalReview article

@article{54b6efbc079242b3a5be281a2d3bc468,
title = "Dialysis-related carnitine disorder",
abstract = "L-carnitine plays an essential role in the β-oxidation of fatty acids by catalyzing their transport into the mitochondrial matrix. The kidney maintains plasma free L-carnitine levels in the homeostatic range by selective saturable tubular reabsorption. The preferential retention of free L-carnitine over acyl-L-carnitines by the kidney is lost in patients with end-stage renal disease (ESRD). Loss of renal parenchyma as a site of carnitine synthesis, as well as nonselective clearance of L-carnitine by the dialysis procedure lead to dialysis-related carnitine deficiency. Numerous studies investigating whether L-carnitine supplementation will alleviate several dialysis-related symptoms, such as intradialytic hypotension, heart failure, muscle weakness, low exercise capacity, and anemia, have reported conflicting results. Many of these studies suffer from a lack of randomization and control groups, heterogeneity in the administration of L-carnitine, and nonstandardized measures of symptom improvement. More data exist to support the use of L-carnitine in selected anemic dialysis patients with very large erythropoietin requirements in whom extensive examination for reversible causes of anemia was unrevealing.",
author = "{Susan Hedayati}, S.",
year = "2006",
month = "7",
day = "1",
doi = "10.1111/j.1525-139X.2006.00180.x",
language = "English (US)",
volume = "19",
pages = "323--328",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Dialysis-related carnitine disorder

AU - Susan Hedayati, S.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - L-carnitine plays an essential role in the β-oxidation of fatty acids by catalyzing their transport into the mitochondrial matrix. The kidney maintains plasma free L-carnitine levels in the homeostatic range by selective saturable tubular reabsorption. The preferential retention of free L-carnitine over acyl-L-carnitines by the kidney is lost in patients with end-stage renal disease (ESRD). Loss of renal parenchyma as a site of carnitine synthesis, as well as nonselective clearance of L-carnitine by the dialysis procedure lead to dialysis-related carnitine deficiency. Numerous studies investigating whether L-carnitine supplementation will alleviate several dialysis-related symptoms, such as intradialytic hypotension, heart failure, muscle weakness, low exercise capacity, and anemia, have reported conflicting results. Many of these studies suffer from a lack of randomization and control groups, heterogeneity in the administration of L-carnitine, and nonstandardized measures of symptom improvement. More data exist to support the use of L-carnitine in selected anemic dialysis patients with very large erythropoietin requirements in whom extensive examination for reversible causes of anemia was unrevealing.

AB - L-carnitine plays an essential role in the β-oxidation of fatty acids by catalyzing their transport into the mitochondrial matrix. The kidney maintains plasma free L-carnitine levels in the homeostatic range by selective saturable tubular reabsorption. The preferential retention of free L-carnitine over acyl-L-carnitines by the kidney is lost in patients with end-stage renal disease (ESRD). Loss of renal parenchyma as a site of carnitine synthesis, as well as nonselective clearance of L-carnitine by the dialysis procedure lead to dialysis-related carnitine deficiency. Numerous studies investigating whether L-carnitine supplementation will alleviate several dialysis-related symptoms, such as intradialytic hypotension, heart failure, muscle weakness, low exercise capacity, and anemia, have reported conflicting results. Many of these studies suffer from a lack of randomization and control groups, heterogeneity in the administration of L-carnitine, and nonstandardized measures of symptom improvement. More data exist to support the use of L-carnitine in selected anemic dialysis patients with very large erythropoietin requirements in whom extensive examination for reversible causes of anemia was unrevealing.

UR - http://www.scopus.com/inward/record.url?scp=33746237574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746237574&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2006.00180.x

DO - 10.1111/j.1525-139X.2006.00180.x

M3 - Review article

C2 - 16893411

AN - SCOPUS:33746237574

VL - 19

SP - 323

EP - 328

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 4

ER -